Recent 8-K filings for UTHR

• May 6, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases

  UTHR Q1 revenue falls 2% to $781.5M; net income down 15%; $2B buyback

  Total revenues $781.5M (-2% YoY); net income $274.9M (-15%); diluted EPS $5.82 vs $6.63.

• March 30, 2026, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  United Therapeutics' TETON-1 Tyvaso meets primary endpoint; FVC improvement 130.1 mL (p<0.0001)

  TETON-1 met primary endpoint: change in absolute FVC by 130.1 mL vs placebo (p<0.0001) at week 52.

• March 9, 2026, 7:59 PM ET other material materiality 0.75 positive item 1.01item 7.01item 9.01 ◈ Material Agreements ×2

  United Therapeutics authorizes $2B buyback, enters $1.5B accelerated share repurchase with Citi

  Board approves up to $2B stock repurchase program through March 9, 2027.

• March 2, 2026, 6:59 PM ET other material materiality 0.85 positive item 7.01item 9.01

  United Therapeutics' ralinepag phase 3 meets primary endpoint; 55% risk reduction in PAH clinical worsening

  Ralinepag reduced risk of clinical worsening by 55% vs placebo (HR 0.45, p<0.0001) in phase 3 ADVANCE OUTCOMES study.

• February 25, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  United Therapeutics reports record $3.18B FY2025 revenue; EPS $27.86 diluted

  FY 2025 revenue hit record $3.18B (+11% YoY); net income $1.33B ($27.86 diluted EPS) vs $1.20B ($24.64) in 2024.

• January 22, 2026, 6:59 PM ET leadership materiality 0.50 neutral item 5.02item 5.03item 7.01item 9.01 ◈ Governance Changes

  United Therapeutics appoints Kevin J. Tracey to board; bylaws amended to lower shareholder vote threshold

  Kevin J. Tracey, M.D., appointed to board effective Jan 21, 2026; awarded 1,220 RSUs under director compensation plan.

• October 29, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  United Therapeutics reports record Q3 revenue $799.5M (+7% YoY); EPS $7.16 diluted, TETON-2 breakthrough

  Revenue $799.5M (+7% YoY); net income $338.7M (+10%); diluted EPS $7.16 vs $6.39.

• September 2, 2025, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  United Therapeutics' Tyvaso succeeds in TETON-2 IPF study, shows 95.6mL FVC improvement

  TETON-2 met primary endpoint: Tyvaso improved absolute FVC by 95.6 mL vs placebo at week 52 (p<0.0001).

• August 1, 2025, 7:59 PM ET other material materiality 0.75 positive item 1.01item 7.01item 9.01

  United Therapeutics enters $1B accelerated share repurchase agreements with Citibank

  Two ASR agreements with Citibank: $500M uncollared and $500M collared; total upfront payment $1B due Aug 4, 2025.

• July 30, 2025, 7:59 PM ET earnings materiality 0.90 positive item 2.02item 9.01

  United Therapeutics Reports Record Q2 2025 Revenue of $798.6M, Authorizes $1B Buyback

  Record total revenue of $798.6 million, up 12% year-over-year, driven by Tyvaso DPI growth of 22% to $315 million.

• June 27, 2025, 7:59 PM ET other material materiality 0.45 neutral item 5.02item 5.07item 9.01

  Shareholders approve amended 2015 Stock Incentive Plan; increase share reserve by 950k shares and extend plan to 2035

  Shareholders approved amendment to 2015 Stock Incentive Plan, increasing share reserve by 950,000 shares to 14,770,000 total.

• April 30, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  United Therapeutics reports record Q1 revenue of $794.4M, up 17% YoY, EPS $6.63

  Total revenues $794.4M (+17% YoY); net income $322.2M (+5%); diluted EPS $6.63 (+7% from $6.17).

• April 28, 2025, 7:59 PM ET debt materiality 0.50 neutral item 1.01item 1.02item 2.03item 9.01

  United Therapeutics enters $2.5B revolving credit facility, repays $200M of existing debt

  New $2.5B unsecured revolving credit facility, with option to increase by up to $750M.

• February 26, 2025, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  United Therapeutics reports record $2.88B revenue in FY2024, up 24% YoY

  Q4 revenue $735.9M (+20% YoY); net income $301.3M vs $217.1M in Q4 2023.

• January 13, 2025, 6:59 PM ET other material materiality 0.20 neutral item 7.01item 9.01

  United Therapeutics presents at J.P. Morgan Healthcare Conference; no specific financials disclosed in filing

  Presentation slides filed as Exhibit 99.1 but full content not provided in the filing text.

• October 30, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  United Therapeutics Q3 revenue $748.9M (+23% YoY); net income $309.1M (+16%)

  Total revenues $748.9M, +23% YoY; net income $309.1M ($6.39 diluted EPS) vs $267.6M ($5.38).

• July 31, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  United Therapeutics Q2 2024 revenue up 20% to $714.9M, EPS $5.85

  Total revenues $714.9M (+20% YoY); net income $278.1M ($5.85 diluted EPS) vs $259.2M ($5.24) in Q2 2023.

• June 27, 2024, 7:59 PM ET leadership materiality 0.50 neutral item 5.02item 5.07item 7.01item 9.01

  United Therapeutics shareholders elect Jan Malcolm to board, approve stock plan amendment adding 1.32M shares

  Jan Malcolm, former Minnesota Health Commissioner, elected to board; replaces Prof. Katherine Klein who did not stand for re-election.

• May 1, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  United Therapeutics Q1 2024 revenue up 34% to $677.7M; net income $306.6M

  Total revenues $677.7M (+34% YoY); Tyvaso product line grew 56% to $372.5M.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event earnings

13 positive 1 negative 5 neutral

source · UTHR on sec.gov